FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
VHVolker HeinemannLFLudwig Fischer von WeikersthalTDThomas DeckerAKAlexander KianiUVUrsula Vehling‐Kaiser
Klinikum St. Marien Amberg · Bayreuth Medical Center · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,736
total citations
- FWCI
- 91.29
- Percentile
- 100%
- References
- 28
Citations per year
Authors
27Topics & keywords
Topics
Keywords
- FOLFIRI
- Medicine
- Bevacizumab
- Cetuximab
- Irinotecan
- Internal medicine
- Colorectal cancer
- KRAS
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.